Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its Use
Anthony B. Hodsman,
Douglas C. Bauer,
David W. Dempster,
Larry Dian,
David A. Hanley,
Steven T. Harris,
David L. Kendler,
Michael R. McClung,
Paul D. Miller,
Wojciech P. Olszynski,
Eric Orwoll and
Chui Kin Yuen
Department of Medicine (A.B.H.), University of Western Ontario, London, Ontario, Canada N6A 4V2; Department of Medicine, Epidemiology, and Biostatistics, Division of Medicine (D.C.B.), University of California, San Francisco, California 94105-3411; Department of Pathology (D.W.D.), Columbia University, New York, New York 10027-6902; Regional Bone Center (D.D.), Helen Hayes Hospital, West Haverstraw, New York 10993; Division of Geriatric Medicine (L.D.), University of British Columbia, Vancouver, British Columbia, Canada V6T 2B5; Division of Endocrinology and Metabolism, Department of Medicine (D.A.H.), University of Calgary, Calgary, Alberta, Canada T2N 4N1; Department of Medicine (S.T.H.), University of California, San Francisco, California 94117-3619; Department of Medicine and Endocrinology (D.L.K.), Osteoporosis Research Centre, University of British Columbia, Vancouver, British Columbia, Canada V5Z 2N6; Oregon Osteoporosis Center and Department of Medical Education (M.R.M.), Providence Portland Medical Center, Portland, Oregon 97213; Department of Medicine, University of Colorado Medical School, and Colorado Center for Bone Research (P.D.M.), Lakewood, Colorado 80227; Department of Medicine, University of Saskatchewan, and Saskatoon Osteoporosis Centre (W.P.O.), Saskatoon, Saskatchewan, Canada S7K 0H6; Department of Medicine and General Clinical Research Centre (E.O.), Oregon Health & Sciences University, Portland, Oregon 97201-3079; and Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Manitoba, and Manitoba Clinic (C.K.Y.), Winnipeg, Manitoba, Canada R3A 1M3
Correspondence: Address all correspondence and requests for reprints to: Anthony B. Hodsman, Professor of Medicine, University of Western Ontario,
St. Joseph’s Health Care, Room 2F-15, 268, Grosvenor Street, London, Ontario N6A 4V2, Canada. E-mail: anthony.hodsman{at}sjhc.london.on.ca
All therapies currently recommended for the management of osteoporosisact mainly to inhibit bone resorption and reduce bone remodeling.PTH and its analog, teriparatide [recombinant human PTH(1–34)],represent a new class of anabolic therapies for the treatmentof severe osteoporosis, having the potential to improve skeletalmicroarchitecture. Significant reductions in both vertebraland appendicular fracture rates have been demonstrated in thephase III trial of teriparatide, involving elderly women withat least one prevalent vertebral fracture before the onset oftherapy. However, there is as yet no evidence that the antifractureefficacy of PTH will be superior to the bisphosphonates, whereascost-utility estimates suggest that teriparatide is significantlymore expensive.
Teriparatide should be considered as treatment for postmenopausalwomen and men with severe osteoporosis, as well as for patientswith established glucocorticoid-induced osteoporosis who requirelong-term steroid treatment. Teriparatide should also be consideredfor the management of individuals at particularly high riskfor fractures, including subjects who are younger than age 65and who have particularly low bone mineral density measurements(T scores 3.5). Teriparatide therapy is not recommended formore than 2 yr, based, in part, on the induction of osteosarcomain a rat model of carcinogenicity.
Total daily calcium intake from both supplements and dietarysources should be limited to 1500 mg together with adequatevitamin D intake (1000 U/d). Monitoring of serum calcium maybe safely limited to measurement after 1 month of treatment;mild hypercalcemia may be treated by withdrawing dietary calciumsupplements, reducing the dosing frequency of PTH, or both.At present, concurrent therapy with antiresorptive therapy,particularly bisphosphonates, should be avoided, although sequentialtherapy with such agents may consolidate the beneficial effectsupon the skeleton after PTH is discontinued.
This article has been cited by other articles:
M. Mulgund, K. A. Beattie, A. K. O. Wong, A. Papaioannou, and J. D. Adachi Assessing adherence to teriparatide therapy, causes of nonadherence and effect of adherence on bone mineral density measurements in osteoporotic patients at high risk for fracture
Therapeutic Advances in Musculoskeletal Diseases,
October 1, 2009;
1(1):
5 - 11.
[Abstract][PDF]
M. Kneissel The Promise of Sclerostin Inhibition for the Treatment of Osteoporosis
IBMS BoneKEy,
July 1, 2009;
6(7):
259 - 264.
[Full Text][PDF]
M. S. LeBoff, R. Narweker, A. LaCroix, L. Wu, R. Jackson, J. Lee, D. C. Bauer, J. Cauley, C. Kooperberg, C. Lewis, et al. Homocysteine Levels and Risk of Hip Fracture in Postmenopausal Women
J. Clin. Endocrinol. Metab.,
April 1, 2009;
94(4):
1207 - 1213.
[Abstract][Full Text][PDF]
G. Lehmann, U. Ott, J. Maiwald, and G. Wolf Bone histomorphometry after treatment with teriparatide (PTH 1-34) in a patient with adynamic bone disease subsequent to parathyroidectomy
NDT Plus,
February 1, 2009;
2(1):
49 - 51.
[Abstract][Full Text][PDF]
M. Wan, C. Yang, J. Li, X. Wu, H. Yuan, H. Ma, X. He, S. Nie, C. Chang, and X. Cao Parathyroid hormone signaling through low-density lipoprotein-related protein 6
Genes & Dev.,
November 1, 2008;
22(21):
2968 - 2979.
[Abstract][Full Text][PDF]
H. Kaji, M. Yamauchi, R. Nomura, and T. Sugimoto Improved Peripheral Cortical Bone Geometry after Surgical Treatment of Primary Hyperparathyroidism in Postmenopausal Women
J. Clin. Endocrinol. Metab.,
August 1, 2008;
93(8):
3045 - 3050.
[Abstract][Full Text][PDF]
T. Kawano, N. Troiano, D. J. Adams, J. Jun Wu, B.-h. Sun, and K. Insogna The Anabolic Response to Parathyroid Hormone Is Augmented in Rac2 Knockout Mice
Endocrinology,
August 1, 2008;
149(8):
4009 - 4015.
[Abstract][Full Text][PDF]
N. Ono, K. Nakashima, S. R. Rittling, E. Schipani, T. Hayata, K. Soma, D. T. Denhardt, H. M. Kronenberg, Y. Ezura, and M. Noda Osteopontin Negatively Regulates Parathyroid Hormone Receptor Signaling in Osteoblasts
J. Biol. Chem.,
July 11, 2008;
283(28):
19400 - 19409.
[Abstract][Full Text][PDF]
P. Redondo The Hidden Face of Venous Malformations: A Multidisciplinary Therapeutic Approach
Arch Dermatol,
July 1, 2008;
144(7):
922 - 926.
[Full Text][PDF]
E. F. Nemeth Anabolic Therapy for Osteoporosis: Calcilytics
IBMS BoneKEy,
June 1, 2008;
5(6):
196 - 208.
[Abstract][Full Text][PDF]
J. Stroup, M. P. Kane, and A. M. Abu-Baker Teriparatide in the treatment of osteoporosis
Am. J. Health Syst. Pharm.,
March 15, 2008;
65(6):
532 - 539.
[Abstract][Full Text][PDF]
A. D Anastasilakis, D. G Goulis, S. A Polyzos, S. Gerou, V. Pavlidou, G. Koukoulis, and A. Avramidis Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-{kappa}B ligand levels in women with established osteoporosis treated with teriparatide
Eur. J. Endocrinol.,
March 1, 2008;
158(3):
411 - 415.
[Abstract][Full Text][PDF]
E. J. MacLaughlin and C. L. Raehl ASHP Therapeutic Position Statement on the Prevention and Treatment of Osteoporosis in Adults
Am. J. Health Syst. Pharm.,
February 15, 2008;
65(4):
343 - 357.
[Full Text][PDF]
G. L. Barnes, S. Kakar, S. Vora, E. F. Morgan, L. C. Gerstenfeld, and T. A. Einhorn Stimulation of Fracture-Healing with Systemic Intermittent Parathyroid Hormone Treatment
J. Bone Joint Surg. Am.,
February 1, 2008;
90(Supplement_1):
120 - 127.
[Abstract][Full Text][PDF]
J. E. Aubin, R. Bouillon, T. A. Guise, and I. R. Reid Meeting Report from the 17th Scientific Meeting of the International Bone and Mineral Society: June 24-29, 2007 in Montreal, Quebec, Canada
IBMS BoneKEy,
November 1, 2007;
4(11):
299 - 313.
[Full Text][PDF]
P. D. Miller, J. P. Bilezikian, M. Diaz-Curiel, P. Chen, F. Marin, J. H. Krege, M. Wong, and R. Marcus Occurrence of Hypercalciuria in Patients with Osteoporosis Treated with Teriparatide
J. Clin. Endocrinol. Metab.,
September 1, 2007;
92(9):
3535 - 3541.
[Abstract][Full Text][PDF]
C. J. Xian Roles of Epidermal Growth Factor Family in the Regulation of Postnatal Somatic Growth
Endocr. Rev.,
May 1, 2007;
28(3):
284 - 296.
[Abstract][Full Text][PDF]
J. Fairman, C. Compher, J. Morris, and J. L. Mullen Living Long With Short Bowel Syndrome: A Historical Case of Twenty-Nine Years of Living With Home Parenteral Nutrition
JPEN J Parenter Enteral Nutr,
March 1, 2007;
31(2):
127 - 134.
[Abstract][Full Text][PDF]
F. Jakob, F. Marin, E. Martin-Mola, D. Torgerson, P. Fardellone, S. Adami, N.C. Thalassinos, D. Sykes, J. Melo-Gomes, C. Chinn, et al. Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO)
QJM,
August 1, 2006;
99(8):
531 - 543.
[Abstract][Full Text][PDF]
A. Hodsman, A. Papaioannou, and A. Cranney Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis.
Can. Med. Assoc. J.,
July 4, 2006;
175(1):
48 - 48.
[Full Text][PDF]
A. Cranney, A. Papaioannou, N. Zytaruk, D. Hanley, J. Adachi, D. Goltzman, T. Murray, A. Hodsman, and for the Clinical Guidelines Committee of Osteoporo Parathyroid hormone for the treatment of osteoporosis: a systematic review.
Can. Med. Assoc. J.,
July 4, 2006;
175(1):
52 - 59.
[Abstract][Full Text][PDF]
U.H. Lerner Bone Remodeling in Post-menopausal Osteoporosis
Journal of Dental Research,
July 1, 2006;
85(7):
584 - 595.
[Abstract][Full Text][PDF]
U.H. Lerner Inflammation-induced Bone Remodeling in Periodontal Disease and the Influence of Post-menopausal Osteoporosis
Journal of Dental Research,
July 1, 2006;
85(7):
596 - 607.
[Abstract][Full Text][PDF]
S. D. Mittelman, G. N. Hendy, R. A. Fefferman, L. Canaff, I. Mosesova, D. E. C. Cole, L. Burkett, and M. E. Geffner A Hypocalcemic Child with a Novel Activating Mutation of the Calcium-Sensing Receptor Gene: Successful Treatment with Recombinant Human Parathyroid Hormone
J. Clin. Endocrinol. Metab.,
July 1, 2006;
91(7):
2474 - 2479.
[Abstract][Full Text][PDF]
D. C. Bauer, P. Garnero, J. P. Bilezikian, S. L. Greenspan, K. E. Ensrud, C. J. Rosen, L. Palermo, D. M. Black, and for the PTH and Alendronate (PaTH) Research Group Short-Term Changes in Bone Turnover Markers and Bone Mineral Density Response to Parathyroid Hormone in Postmenopausal Women with Osteoporosis
J. Clin. Endocrinol. Metab.,
April 1, 2006;
91(4):
1370 - 1375.
[Abstract][Full Text][PDF]
B. T. Summey and G. Yosipovitch Glucocorticoid-Induced Bone Loss in Dermatologic Patients: An Update
Arch Dermatol,
January 1, 2006;
142(1):
82 - 90.
[Abstract][Full Text][PDF]
3.5). Teriparatide therapy is not recommended for more than 2 yr, based, in part, on the induction of osteosarcoma in a rat model of carcinogenicity. 
